Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype

Peckham, Hannah; Cambridge, G; Bourke, Lauren; Sen, Debajit; Radziszewska, Anna; Leandro, Maria; Ioannou, Yiannis

doi:10.1002/art.40117

Cited by 12 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of ACPA in polyarticular RF+ JIA has been shown by numerous studies to confer a greater risk of more aggressive and erosive disease (51, 84, 85, 90, 93, 95–99). This is mirrored in patients with ACPA-positive adult RA, who also have a more severe disease course (98, 100, 101). As with RF, ACPA positivity among children with polyarticular JIA typically leads pediatric rheumatologists to recommend earlier, more aggressive therapy (56).…”

Section: Acpa: Use In Diagnosis and Prognosis Of Jiamentioning

confidence: 87%

Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis

Mahmud

Binstadt

2019

Front. Immunol.

View full text Add to dashboard Cite

Autoantibody production occurs in juvenile idiopathic arthritis (JIA) and numerous other autoimmune diseases. In some conditions, the autoantibodies are clearly pathogenic, whereas in others the roles are less defined. Here we review various autoantibodies associated with JIA, with a particular focus on antinuclear antibodies and antibodies recognizing citrullinated self-antigens. We explore potential mechanisms that lead to the development of autoantibodies and the use of autoantibody testing in diagnosis and prognosis. Finally, we compare and contrast JIA-associated autoantibodies with those found in adults with rheumatoid arthritis (RA).

show abstract

Section: Acpa: Use In Diagnosis and Prognosis Of Jiamentioning

confidence: 87%

Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis

Mahmud

Binstadt

2019

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…While the contribution of ANA to disease pathology remains unclear, recent research has suggested that ANA positivity is associated with the development of ectopic lymphoid tissue in certain JIA patients, which by facilitating interactions between autoreactive T and B cells could directly support the production of these autoantibodies (33). In contrast to RF- poly-JIA, RF+ poly-JIA has a later onset, and many clinical and genetic features (34) that are analogous with adult-onset rheumatoid arthritis (RA), including the development of anti-citrullinated (anti-CCP) and RF autoantibodies (35). Furthermore, the multinational JIA consortium for Immunochip (JACI) recently established that RF+ poly-JIA is more genetically similar to adult-onset RA than to oligo-JIA and RF- poly-JIA (34).…”

Section: Juvenile Idiopathic Arthritismentioning

confidence: 99%

B Cells as a Therapeutic Target in Paediatric Rheumatic Disease

Wilkinson

Rosser

2019

Front. Immunol.

View full text Add to dashboard Cite

B cells carry out a central role in the pathogenesis of autoimmune disease. In addition to the production of autoantibodies, B cells can contribute to disease development by presenting autoantigens to autoreactive T cells and by secreting pro-inflammatory cytokines and chemokines which leads to the amplification of the inflammatory response. Targeting both the antibody-dependent and antibody-independent function of B cells in adult rheumatic disease has led to the advent of B cell targeted therapies in clinical practice. To date, whether B cell depletion could also be utilized for the treatment of pediatric disease is relatively under explored. In this review, we will discuss the role of B cells in the pathogenesis of the pediatric rheumatic diseases Juvenile Idiopathic Arthritis (JIA), Juvenile Systemic Lupus Erythematosus (JSLE) and Juvenile Dermatomyositis (JDM). We will also explore the rationale behind the use of B cell-targeted therapies in pediatric rheumatic disease by highlighting new case studies that points to their efficacy in JIA, JSLE, and JDM.

show abstract

“…In children, autoimmune inflammatory arthritis is classified under the umbrella term of JIA and is also one of the most common rheumatic diseases in children and adolescents. JIA terminology encompasses many types of arthritis, which are pathologically distinct from RA with the exception of the rheumatoid factor (RF) positive polyarticular JIA phenotype, present in less than 10% JIA patients which is clinically, serologically and genetically similar to the RA phenotype in adults ( 21 , 22 ). For simplicity, in this review, we will focus on studies in patients with oligo-articular JIA (oligo-JIA), which is the most common phenotype in children, and polyarticular-JIA (poly-JIA), where, as described above, there is some overlap with the pathogenesis of RA ( 23 ).…”

Section: Immune Dysregulation In Rheumatoid Arthritis and Juvenile Idmentioning

confidence: 99%

Exploring the Evidence for an Immunomodulatory Role of Vitamin D in Juvenile and Adult Rheumatic Disease

et al. 2021

View full text Add to dashboard Cite

Vitamin D is synthesized in the skin following exposure to UVB radiation or is directly absorbed from the diet. Following hydroxylation in the liver and kidneys, vitamin D becomes its bioactive form, 1,25(OH)2D, which has been described to have potent immunomodulatory capacity. This review will focus on the effect of vitamin D in modulating the dysregulated immune system of autoimmune rheumatic diseases (ARD) patients across age, in particular in arthritis (rheumatoid arthritis and juvenile idiopathic arthritis), and systemic lupus erythematosus (with adult and juvenile onset). As well as delineating the impact of vitamin D on the innate and adaptive immune functions associated with each disease pathology, this review will also summarize and evaluate studies that link vitamin D status with disease prevalence, and supplementation studies that examine the potential benefits of vitamin D on disease outcomes. Exploring this evidence reveals that better designed randomized controlled studies are required to clarify the impact of vitamin D supplementation on ARD outcomes and general health. Considering the accessibility and affordability of vitamin D as a therapeutic option, there is a major unmet need for evidence-based treatment recommendations for the use of vitamin D in this patient population.

show abstract

Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype

Cited by 12 publications

References 32 publications

Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis

Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis

B Cells as a Therapeutic Target in Paediatric Rheumatic Disease

Exploring the Evidence for an Immunomodulatory Role of Vitamin D in Juvenile and Adult Rheumatic Disease

Contact Info

Product

Resources

About